Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Alembic receives EIR from USFDA for facility at Panelav
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
The Ma’anshan site approval covers pastilles, oral liquids, and powders
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Subscribe To Our Newsletter & Stay Updated